Ask AI

Clinical Focus in KRAS-Mutated Low-Grade Serous Ovarian Cancer: Integrating a Novel Dual MEK/FAK Inhibitor Into Practice

Enhance your understanding of clinical evidence supporting the use of MEK/FAK-targeted agents in patients with KRAS-mutated low-grade serous ovarian cancer and how to effectively manage adverse events associated with their use through a podcast, expert-written ClinicalThought commentary, and certified text module with accompanying downloadable slides.

Share

Program Content

Activities

New Targeted Combination for LGSOC
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: November 06, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Verastem, Inc.

Verastem, Inc.